homologous recombination repair deficiency
Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response
The collaboration between Mass General and Switzerland's Lunaphore will initially focus on developing a test for ovarian, breast, and prostate cancers.
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.